JP2003246728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003246728A5 JP2003246728A5 JP2002369185A JP2002369185A JP2003246728A5 JP 2003246728 A5 JP2003246728 A5 JP 2003246728A5 JP 2002369185 A JP2002369185 A JP 2002369185A JP 2002369185 A JP2002369185 A JP 2002369185A JP 2003246728 A5 JP2003246728 A5 JP 2003246728A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- animal
- feed
- salt
- ornithine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 5
- 229960003104 ornithine Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 206010063493 Premature ageing Diseases 0.000 claims 3
- 208000032038 Premature aging Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002369185A JP2003246728A (ja) | 2001-12-21 | 2002-12-20 | クロソ蛋白質発現量の減少により引きおこされる疾患の治療または予防剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001389912 | 2001-12-21 | ||
| JP2001-389912 | 2001-12-21 | ||
| JP2002369185A JP2003246728A (ja) | 2001-12-21 | 2002-12-20 | クロソ蛋白質発現量の減少により引きおこされる疾患の治療または予防剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003246728A JP2003246728A (ja) | 2003-09-02 |
| JP2003246728A5 true JP2003246728A5 (enExample) | 2005-08-18 |
Family
ID=28677010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002369185A Pending JP2003246728A (ja) | 2001-12-21 | 2002-12-20 | クロソ蛋白質発現量の減少により引きおこされる疾患の治療または予防剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2003246728A (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007031375A (ja) * | 2005-07-28 | 2007-02-08 | Kyowa Hakko Kogyo Co Ltd | 肌質改善用経口剤 |
| JP2017019726A (ja) * | 2015-07-07 | 2017-01-26 | 佐々木食品工業株式会社 | Ｅｌｏｖｌ６阻害、ＮＡＳＨの予防又は治療並びにインスリン抵抗性改善用組成物 |
| WO2021200996A1 (ja) * | 2020-03-30 | 2021-10-07 | 味の素株式会社 | 骨強度低下の予防又は改善用組成物 |
-
2002
- 2002-12-20 JP JP2002369185A patent/JP2003246728A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY176679A (en) | Use of nutritional compositions for preventing disorders | |
| EP3335710A3 (en) | Use of nutritional compositions for preventing disorders | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| MXPA04005582A (es) | Alimento o composicion de alimento para mascotas que contiene extracto de plantas para la salud osea. | |
| WO2005007652A3 (en) | Substituted quinolin-4-ylamine analogues | |
| CA2433714A1 (en) | Arthritis preventing or treating agent | |
| WO2009055799A3 (en) | Compositions and methods for treatment of diseases of the foot of an animal | |
| WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| WO2020158632A1 (ja) | 機能水 | |
| WO2004093881A3 (en) | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors | |
| EP1637137A3 (en) | Method and composition for administering a cyclooxygenase-2 inhibitor to animals | |
| ATE252847T1 (de) | Gesunde hundefuttermittel | |
| JP2008500376A5 (enExample) | ||
| ATE409028T1 (de) | Arzneien zur behandlung von nervenerkrankungen | |
| JP2003246728A5 (enExample) | ||
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| Motluk | It's a wonderful lie | |
| WO2004056768A3 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
| PL374083A1 (en) | Sgk and nedd used as diagnostic and therapeutic targets | |
| HU0102987D0 (en) | Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient | |
| CA2489208A1 (en) | Interleukin-6 suppressive agent | |
| WO2004093867A3 (en) | Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use | |
| WO2007096596A3 (en) | Use of il-8 for the treatment of crohn' s disease | |
| TW200510379A (en) | 1, 4-disubstituted piperidine compounds, their preparation and use as medicaments |